Anti-factor xa activity of standard and Japan-specific doses of rivaroxaban in thai patients with non-valvular atrial fibrillation
© 2020 Japanese Circulation Society. All rights reserved. Background: Recommended rivaroxaban doses for stroke prevention in atrial fibrillation (SPAF) are 20 and 15 mg/day in patients with normal and reduced renal function, respectively, but lower doses (15 and 10 mg) have been tested and approved...
Saved in:
Main Authors: | Wanwarang Wongcharoen, Phongsathon Pacharasupa, Lalita Norasetthada, Siriluck Gunaparn, Arintaya Phrommintikul |
---|---|
Format: | Journal |
Published: |
2020
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85087111274&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70833 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation
by: Wanwarang Wongcharoen, et al.
Published: (2018) -
Anti–Factor Xa Activity of Fixed-Dose Fondaparinux in Low-Body-Weight Patients With Acute Coronary Syndrome
by: Wanwarang Wongcharoen, et al.
Published: (2020) -
Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study
by: Laura Fanning, et al.
Published: (2020) -
Atrial fibrillation in heart failure
by: Wanwarang Wongcharoen, et al.
Published: (2018) -
Causes of death of patients with non-valvular atrial fibrillation in Asians
by: Krittayaphong R.
Published: (2023)